Drug name - Bydureon

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(1 year, 11 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(1 year, 11 months ago)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Oct, 2022

(12 days from now)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Apr, 2023

(6 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Dec, 2025

(3 years from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method Apr, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element Nov, 2027

(5 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Dec, 2027

(5 years from now)

US8216180 ASTRAZENECA AB Administering apparatus with functional drive element Jan, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US9320853 ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule Mar, 2028

(5 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps Mar, 2028

(5 years from now)

US8758292

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element May, 2028

(5 years from now)

US8216180

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element Jul, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Sep, 2028

(5 years from now)

US8439864

(Pediatric)

ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps Sep, 2028

(6 years from now)

US9320853

(Pediatric)

ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule Sep, 2028

(6 years from now)

US8827963 ASTRAZENECA AB Administering device with holding mechanism Feb, 2029

(6 years from now)

US8690837 ASTRAZENECA AB Mixing device for a two-chamber ampoule May, 2029

(6 years from now)

US8827963

(Pediatric)

ASTRAZENECA AB Administering device with holding mechanism Aug, 2029

(6 years from now)

US8690837

(Pediatric)

ASTRAZENECA AB Mixing device for a two-chamber ampoule Nov, 2029

(7 years from now)

US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder Jul, 2030

(7 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder Jul, 2030

(7 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

availability in other generic markets.

Click on the highlighted region to filter.